Author [ref.] Study type Number of LYP patients treated with RT Number of LYP lesions treated Associated lymphoma Locations of treated lesion TNM stage at presentation Other treatments RT details CR rate LR Time to LR (m) Follow-up (m)
Thomsen and Schmidt [21 ] E 1 1 MF n/s T3bN0 Topical 5-FU, topical steroids, PUVA Localized RT 100% Y n/s
Willemze et al. [15 ]
R
1
2
LCL n/s TSEBR, 40 Gy, 4 MeV 100% Y 3 n/s Localized RT, 25 Gy, 100 kV 100% Y 5
Sanchez et al. [16 ]
R
4 MF n/s T3aN0 Topical corticosteroids, photochemotherapy, chlorambucil, prednisone, combination chemotherapy TSEBR, 30 Gy, 6 MeV e− 0% N MF n/s T3aN0 Topical nitrogen mustard Localized RT 0% N HL n/s Mustine HCL, vincristine, sulfate, prednisone, procarbazine HCL 100% Y n/s ML n/s Localized RT 0% N
Sina and Burnett22 ]
R
2
2 Left thigh T3bN0 Localized RT, 6/2 Gy, 15 kV, 30 mm HVL 100% N 14 n/s T3bN0 Localized RT 100% N 36
Kaufmann19 ]
R
1
2 Right forearm T1bN0 Localized RT, 35/2–2.5 Gy, 6 MeV e− , 0.5 cm bolus, 90% IDL 100% N Right finger Localized RT, 30/2 Gy, 6 MeV e− 100% N
Wilson et al. [18 ] R 3 n/s T1-3Nx Topical steroids, PUVA, topical nitrogen mustard TSEBR/6 fields, 36/1 Gy, 6 MeV e− , supplemented 20/1 Gy, 120 kV to perineum, soles of feet and 6/2 Gy, 120 kV to apical scalp 100% Y 4.8; 3-year DFS 20% 44.1 (median) J. Breneman and D. Breneman17 ] E 5 MF n/s n/s; 1 patient received concurrent CHOP TSEBR/modified Stanford, 36 Gy 80% N 12, 48, 61, and 70 Christensen et al. [24 ] R 6 6 n/s Localized RT 100% N Cabanillas et al. [3 ] R 4 CTCL/MF/ LCL n/s 0% Y n/s
Kaufmann20 ] R 1 4 Right forearm, left forearm ×3 T1bN0 Localized RT, 30/2 Gy, 6 MeV e− , 0.5 cm bolus daily 100% N 45
Scarisbrick et al. [23 ]
R
2
2 Left flank T2aN0 Localized RT, 8/2 Gy, 100 kV 0% (100% with retreatment) Y 6 12 Lower abdomen T2aN0 Localized RT, 8/2 Gy, 100 kV 100% N 12
25 ].− = electron, HVL = half value layer, LR = local recurrence, and DFS = disease-free survival.